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Abstract An EtOAc extract from the roots of Sopho-
ra flavescens (Kushen) potentiated γ -aminobutyric acid
(GABA)-induced chloride influx in Xenopus oocytes tran-
siently expressing GABAA receptors with subunit composi-
tion, α1β2γ2S. HPLC-based activity profiling of the extract
led to the identification of 8-lavandulyl flavonoids, kushenol
I, sophoraflavanone G, (−)-kurarinone, and kuraridine as
GABAA receptor modulators. In addition, a series of inactive
structurally related flavonoids were characterized. Among
these, kushenol Y (4) was identified as a new natural prod-
uct. The 8-lavandulyl flavonoids are first representatives of a
novel scaffold for the target.
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Introduction
Gamma-aminobutyric acid type A (GABAA) receptors
mediate inhibitory neurotransmission in the brain. The recep-
tors are composed of five subunits forming a central pore
that is permeable for chloride ions upon activation by the
endogenous ligand γ -aminobutyric acid (GABA). Up to now
19 different subunit isoforms have been identified in the
human genome and form GABAA receptors in numerous
combinations [1]. The most abundant GABAA receptor sub-
type is composed of 2α1, 2β2, and 1γ2 subunits. More than
10 subtypes composed of other subunit combinations have
been identified [2], which differ in tissue localization, func-
tional characteristics, and pharmacological properties [3,4].
GABAA receptors possess several binding sites for small
molecules, and are target for numerous drugs used to treat
anxiety, panic, insomnia, and epilepsy [5,6]. However, use
of the most frequently prescribed benzodiazepines is associ-
ated with undesirable side effects including reduced coordi-
nation, cognitive impairment, increased accident proneness,
physiological dependence, and withdrawal symptoms [5,7].
Rational lead discovery approaches are presently not possible
due to the lack of a high-resolution structure of the GABAA
receptor [3,8].
Various natural products modulating GABAA recep-
tors (e.g., flavonoids, monoterpenes, diterpenes, neolignans,
β-carbolines, and polyacetylenes) have been identified [9,
10]. Given the diversity of these natural product ligands
which structurally differ from synthetic GABAA receptor
modulators, we recently initiated a project aiming at the
discovery of GABAA receptor agonists with natural prod-
uct scaffolds new for the target. In a screening of 880 plant
and fungal extracts with an automated functional assay using
Xenopus oocytes expressing human GABAA receptors of the
most abundant subtype composition (α1β2γ2S), an EtOAc
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extract of the traditional Chinese herbal drug Kushen (roots
of Sophora flavescens Aiton, Fabaceae) displayed promising
activity.
HPLC-based activity profiling is a miniaturized and highly
effective approach for localization, dereplication, and charac-
terization of bioactive natural products in extracts [11]. This
approach has been successfully established and used in our
labs with various cell-based and biochemical assays [12–14].
We recently developed and validated a profiling approach for
the discovery of new GABAA receptor ligands [15], which
we subsequently employed to identify scaffolds new for the
target [16,17]. We here describe HPLC-based activity pro-
filing of the active S. flavescens extract, identification of the
active constituents, and preliminary SAR (structure activity
relationship) considerations based on a focused compound
library generated from the extract.
Experimental section
General experimental procedures
Optical rotations were measured on a M341 polarime-
ter (Perkin-Elmer). CD spectra were recorded on a JAS-
CO J-720W spectrophotometer. UV spectra were measured
on Hewlett-Packard 8452A diode array spectrophotometer
(λmax in nm). IR spectra were measured on a Nicolet Magna-
FT-IR-750 spectrometer (νmax in cm−1). NMR spectra were
recorded at 291 K with a Bruker Avance III™ spectrome-
ter operating at 500.13 MHz for 1H, and 125.77 MHz for
13C, respectively. 1H-NMR experiments and 2D homonu-
clear and heteronuclear NMR spectra were measured with
a 1 mm TXI probe, and 13C-NMR spectra were obtained in
3 mm tubes (Armar Chemicals) with a 5 mm BBO probe.
Spectra were analyzed using Bruker TopSpin 2.1 software.
High resolution mass spectra (HPLC–PDA–ESITOFMS)
were obtained on a micro TOF ESI–MS system (Bruker Dal-
tonics) connected via T-splitter (1:10) to an HP 1100 series
system (Agilent) consisting of a binary pump, autosam-
pler, column oven, and diode array detector (G1315B). Data
acquisition and processing was performed using HyStar 3.0
software (Bruker Daltonics). Semi-preparative HPLC sepa-
rations for activity profiling and offline microprobe NMR
was performed with an HP 1100 series system (Agilent)
consisting of a quaternary pump, autosampler, column oven,
and diode array detector (G1315B). Parallel evaporation of
microfractions and semi-preparative HPLC fractions was
performed with an EZ-2 plus vacuum centrifuge (Genevac).
SunFire C18 (3.5 µm, 3.0×150 mm i.d.) and a SunFire Prep
C18 (5 µm, 10 × 150 mm i.d.) columns (Waters) were used
for HPLC–PDA–ESITOFMS and semi-preparative HPLC,
respectively. HPLC-grade acetonitrile (Scharlau Chemie)
and water were used for HPLC separations. Solvents used for
extraction and column chromatography were of analytical
grade. Sephadex LH-20 gel was obtained from Amersham
Biosciences (Uppsala, Sweden). Silica gel 60 F254 pre-
coated Al sheets (0.25 mm) and silica gel 60 GF254 glass
plates (1.00 mm) (both Merck) were used for TLC and prepar-
ative TLC, respectively.
Plant material
Kushen (dried roots of S. flavescens) was purchased from
Yong Quan GmbH (Ennepetal, Germany). A voucher speci-
men (P00414) is deposited at the Institute of Pharmaceutical
Biology, University of Basel.
Extraction
The plant material was frozen with liquid nitrogen and
ground with a ZM1 ultracentrifugal mill (Retsch). The extract
for the screening and HPLC-based activity profiling was
prepared with an ASE 200 extraction system with solvent
module (Dionex) by extraction with ethyl acetate. Extrac-
tion pressure was 120 bar and temperature was set at 70 ◦C.
Extract was obtained by two extraction cycles of 5 min each.
For isolation of larger amounts of pure compounds for phar-
macological testing, 50 g of ground roots were extracted by
maceration at room temperature with petroleum ether (4×0.5
l, 4 h each), followed by ethyl acetate (4 × 0.5 l, 4 h each).
The solvents were evaporated at reduced pressure to yield
0.9 and 2.3 g of petroleum ether and ethyl acetate extract,
respectively. The extracts were stored at −20 ◦C until use.
Microfractionation for activity profiling
Microfractionation for GABAA receptor activity profil-
ing was performed as previously described [15], with
minor modifications: separation was carried out on a semi-
preparative HPLC column with acetonitrile (solvent A) and
water containing 0.1% formic acid (solvent B) using the fol-
lowing gradient: 20% A to 100% A for 30 min, hold at 100%
A for 5 min. The flow rate was 5 mL/ min, and 50 µL of extract
(100 mg/ml in DMSO) were injected. A total of 22 time-
based microfractions of 90 s each were collected. Solvent
removal of microfractions was carried out with a centrifu-
gal evaporator (Genevac AZ-2), and films reconstituted in
DMSO prior to activity testing.
HPLC–PDA–ESITOFMS
The ethyl acetate extract of S. flavescens was analyzed
with acetonitrile (solvent A) and water containing 0.1% for-
mic acid (solvent B) using an optimized gradient profile:
20–100% A in 30 min, 100% A, hold at 100% A for 5 min.
The flow rate was 0.5 mL/ min. The sample was dissolved
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in DMSO at a concentration of 10 mg/mL, and the injection
volume was 10 µL. ESITOFMS spectra were recorded in
the range of m/z 100–1500 in positive ion mode. Nitrogen
was used as a nebulizing gas at a pressure of 2.0 bar and as
a drying gas at a flow rate of 9.0 L/ min (dry gas tempera-
ture 240 ◦C). Capillary voltage was set at 4500 V, hexapole
at 230.0 Vpp. Instrument calibration was performed using
a reference solution of sodium formiate 0.1% in isopropa-
nol/water (1:1) containing 5 mM sodium hydroxide.
Preparative isolation of compounds for GABAA receptor
activity test
A portion (0.8 g) of the ethyl acetate extract was dissolved
in 2 mL of DMSO and the solution was filtered. Separa-
tion of the ethyl acetate extract was carried out with the
same solvent system and gradient elution as for HPLC–
PDA–ESITOFMS. The flow rate was set at 5 mL/ min and
the injected volume of extract was 200 µL at a concentration
of 400 mg/mL in DMSO. A total of 13 peak-based fractions
were collected manually. A total of 10 injections were car-
ried out, and corresponding fractions were combined. Final
purification were as follows: peaks 2–5, 7, 8, and 10–13
were filtered through a Sephadex LH-20 column (300 ×
10 mm, MeOH containing 0.1% formic acid) to yield pure
compounds 3 (5.6 mg), 4 (1.8 mg), 5 (2.3 mg), 6 (3.8 mg),
9 (67 mg), 10 (2.9 mg), 13 (4.3 mg), 14 (3.1 mg), 15 (2.1 mg),
and 16 (1.2 mg). Peak 1 was separated by preparative TLC
(CHCl3:MeOH:formic acid—100:10:0.5) to afford com-
pounds 1 (2.9 mg) and 2 (3.3 mg). Peak 6 was separated by
preparative TLC (CHCl3:MeOH:formic acid—150:10:0.5)
to give compounds 7 (3.4 mg) and 8 (2.2 mg). Peak 9 was also
purified by preparative TLC (CHCl3:MeOH:formic acid—
150:10:0.5) to give compounds 11 (2.4 mg) and 12 (3.6 mg).
Microprobe NMR analysis
1 mm NMR tubes (Bruker) were used for 1H detected 1D
and 2D NMR experiments, and 0.1 mg of the above 16 pure
compounds was dissolved in 10 µl CD3OD. The following
settings were used: 128 scans to record 1H-spectra; 8 scans
for 1H,1 H-COSY spectra using cosygpqf pulse program; 32
scans and 256 increments to record HSQC experiments using
the hsqcedetgp or hsqcetgpsi2 pulse program. HMBC spec-
tra were recorded with 64 scans and 128 increments using
the hmbcgplpndqf pulse program.
Kushenol Y (4)
Light yellow amorphous powder; [α]20D + 22.0(c = 0.17,
MeOH). CD (MeOH) [θ ]315 + 5897, [θ ]293 − 17061. UV
(MeOH) λmax (logε): 287 (4.13), 326 (3.78) nm. IR (film)
νmax: 3401 (br), 2968, 2943, 1651, 1610, and 1268 cm−1.
1H-NMR (500.13 MHz, CD3OD) δ: 1.11 (s, 6H, H-6′′, 7′′),
1.23 (m, 2H, H-3′′), 1.35 (m, 2H, H-4′′), 1.59 (s, 3H, H-10′′),
2.38 (m, 1H, H-2′′), 2.42 (m, 2H, H-1′′), 4.52 (s, 1H, H-9′′),
4.59 (s, 1H, H-9′′), 4.74 (d, 1H, J = 11.6 Hz, H-3), 5.39
(d, 1H, J = 11.6 Hz, H-2), 5.96 (s, 1H, H-6), 6.35 (d, 1H,
J = 2.1 Hz, H-3′), 6.39 (dd, 1H, J = 8.0, 2.1 Hz, H-5′),
7.28 (d, 1H, J = 8.0 Hz, H-6′); 13C-NMR (125.77 MHz,
CD3OD) δ : 196.5 (C-4), 165.7 (C-9), 160.7 (C-7), 158.0
(C-5), 157.9 (C-2′), 155.9 (C-4′), 148.3 (C-8′′), 128.8 (C-6′),
115.2 (C-1′), 110.8 (C-9′′), 108.8 (8), 107.8 (C-5′), 103.6 (C-
10), 100.4 (C-3′), 96.1 (C-6), 78.1 (C-2), 72.7 (C-3), 71.3 (C-
5′′), 46.9 (C-2′′), 41.4 (C-4′′), 26.4 (C-3′′), 28.6 (C-6′′), 27.3
(C-1′′), 28.8 (C-7′′), 18.7 (C-10′′). HREIMS m/z: 481.1846
(calcd. for C25H30O8Na, 481.1838).
Expression of GABAA receptors
Stage V–VI oocytes from Xenopus laevis were prepared and
cRNA was injected as previously described by Khom et al.
[18]. Female X. laevis (NASCO, Fort Atkinson, WI, USA)
were anesthetized by exposing them for 15 min to a 0.2% MS-
222 (methanesulfonate salt of 3-aminobenzoic acid ethyl,
Sigma, Vienna, Austria) solution before surgically remov-
ing parts of the ovaries. Follicle membranes from isolated
oocytes were enzymatically digested with 2 mg/mL collage-
nase (Type 1A, Sigma, Vienna, Austria). Synthesis of capped
run-off poly(A+) cRNA transcripts was obtained from line-
arized cDNA templates (pCMV vector). One day after enzy-
matic isolation, the oocytes were injected with 50 nL of
DEPC-treated water (Sigma) containing different cRNAs at
a concentration of approximately 300–3000 pg/nL per sub-
unit. To ensure expression of α1β2γ2S receptors, rat cRNA
of α1, β2, and γ2S subunits were mixed in a 1:1:10 ratio. The
amount of injected cRNA mixture was determined by means
of a NanoDrop ND-1000 (Kisker Biotech, Steinfurt, Ger-
many). Oocytes were then stored at 18 ◦C in ND96 solution
(90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and
5 mM HEPES; pH 7.4) [19] Voltage clamp measurements
were performed between days 1 and 5 after cRNA injection.
Two-microelectrode voltage clamp studies
Electrophysiological experiments were performed by the
two-microelectrode voltage clamp method making use of a
TURBO TEC-03X amplifier (npi electronic GmbH, Tamm,
Germany) at a holding potential of −70 mV and pCLAMP
10 data acquisition software (Molecular Devices, Sunny-
vale, CA, USA). Currents were low-pass-filtered at 1 kHz
and sampled at 3 kHz. ND 96 solution was used as bath solu-
tion. The electrode filling solution consisted of 2 M KCl.
Oocytes with maximal current amplitudes >3 µA were dis-
carded to exclude voltage clamp errors. Before application
of test solutions, a dose–response experiment with GABA
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Fig. 1 Potentiation of IGABA by Sophora flavescens extract (EtOAc,
100 µg/mL). a The mean IGABA potentiation of 55.0 ± 7.4% (n = 3;
compared to 100% control) was observed. b Chloride currents through
α1β2γ2S GABAA receptors induced by GABA EC3−10 (control; left
column) and currents during co-application of GABA (EC3−10) and
100 µg/mL of the Sophora flavescens extract (right column)
concentrations ranging from 0.1 to 1 mM was performed to
determine GABA EC3−10 (typically between 3 and 10 µM).
Test solution application
Test solutions were applied by means of a ScreeningTool
(npi electronic GmbH, Tamm, Germany) automated fast per-
fusion system [20] As previously described, microfractions
collected from the semi-preparative HPLC separations were
dissolved in 30 µL DMSO and mixed with 2.97 mL of bath
solution [15]. After addition of GABA EC3−10, 100 µL of
this solution was applied to the oocytes at a perfusion speed
of 300 µL/s. Stock solutions of compounds 6–16 (10 mM in
DMSO) were diluted to a concentration of 100 µM with bath
solution and then mixed with GABA EC3−10. Of each solu-
tion,100 µLwasapplied to theoocytesataspeedof300 µL/s.
Data analysis
Enhancement of the chloride current (IGABA) was defined as
I(GABA+Comp)/IGABA−1, where I(GABA+Comp) is the current
response in the presence of a given compound, and IGABA is
the control GABA induced current. Concentration–response
curves were generated, and the data were fitted by nonlinear
regression analysis using ORIGIN software (OriginLab Cor-





)nH , where EC50 is the concentration of the
compound that increases the amplitude of the GABA-evoked
current by 50%, and nH is the Hill coefficient. Data are given
as mean±S.E. of at least two oocytes and ≥2 oocyte batches.
Results and discussion
Extracts were screened by means of an automated, fast
perfusion system during two-microelectrode voltage clamp
Fig. 2 HPLC-based activity profiling of Sophora flavescens extract
(EtOAc) for GABAA receptor modulating properties. b The HPLC chro-
matogram (254 nm) of a semi-preparative separation of 5 mg extract
is shown. a Potentiation (in %) of IGABA through α1β2γ2S GABAA
receptors by 27 fractions of 90 s each fraction is shown above. c Repre-
sentative currents through α1β2γ2S GABAA receptors in the presence
of GABA (EC3−10, single bar, control) and currents recorded during
co-application of GABA (EC3−10) and the indicated fraction (double
bar). Current recordings for four most active fractions (11, 12, 14, and
15) are shown
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Fig. 3 a The optimized HPLC separation for LC–PDA–TOFMS anal-
ysis of the EtOAc extract is shown. Peak labeling corresponds to com-
pounds 1–16. 200 µg extract in 20 µL DMSO were injected. The HPLC
trace was recorded at 254 nm. b The chromatogram (254 nm) of the
optimized, semi-preparative HPLC separation of the EtOAc extract
(80 mg in 200 µL DMSO) is shown. Peaks 1–13 were collected for
microprobe NMR and further purified if required
measurements in Xenopus oocytes expressing functional
GABAA receptors with defined subunit composition (α1β2γ2S)
[20]. When tested at 100 µg/mL, the S. flavescens EtOAc
extract enhanced GABA induced chloride ion current (IGABA)
by 55.0 ± 7.4% (n = 3, Fig. 1).
The extract was then submitted to HPLC-based activ-
ity profiling using a previously validated protocol [15].
The chromatogram of a semi-preparative separation of 5 mg
extract, the corresponding potentiation of IGABA by the
time-based fractionations (27 microfractions of 90 s each),
and representative currents of the most active fractions are
shown in Fig. 2. Fractions 11 and 12 displayed the high-
est potentiation of IGABA (155.6 ± 22.2%, n = 2 and
135.1 ± 6.6%, n = 2, respectively). These fractions con-
tained the major compounds of the extract. Fractions 14 and
15 potentiated IGABA to a lesser extent (45.0 ± 5.0%, n = 2
and 62.5 ± 12.5%, n = 2, respectively), while the effects
of fractions 9, 18, 19, and 21 were not significantly different
from zero (P > 0.05, see Fig. 2).
Considering that some HPLC peaks showed partial over-
lap, separation conditions were optimized for full resolution
of the critical HPLC peaks. These conditions were then used
to measure high-resolution LC–MS data (Fig. 3a; Table 1).
Results of the HPLC–PDA–TOFMS analysis and a data-
base search are summarized in Table 1. The same optimized
conditions were also used in preparative isolation of tar-
get compounds. A typical semi-preparative HPLC chromato-
gram obtained with an injection of 80 mg of extract is shown
in Fig. 3b. A total of 13 peaks were collected and submit-
ted to further purification with Sephadex LH-20 column and
preparative TLC to afford 16 compounds for which 1D and
2D NMR spectra were recorded with a 1 mm TXI probe. The
purity was checked by analytical HPLC under conditions as
in Fig. 3a.
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Table 1 Key data from HPLC–PDA–ESITOFMS analysis, semi-preparative HPLC, and database search for compounds 1–16
Cpd Rt1(min)a Rt2(min)b λmax (nm) Accurate mass
[M + Na]+ found
Accurate mass
[M + Na]+ calc.
Molecular formula DNP hitsc
1 12.6 9.4 207, 288, 328 495.1987 495.1995 C26H32O8 2
2 12.6 9.4 207, 288, 328 495.1987 495.1995 C26H32O8 2
3 13.4 10.3 210, 292, 338 479.2055 479.2046 C26H32O7 3
4 13.9 11.7 209, 287, 326 481.1846 481.1838 C25H30O8 1
5 15.3 12.5 212, 293, 340 479.2035 479.2046 C26H32O7 3
6 15.8 13.3 210, 292, 338 465.1901 465.1889 C25H30O7 2
7 16.9 14.2 212, 290, 333 477.1896 477.1889 C26H30O7 5
8 16.9 14.2 212, 290, 333 477.1896 477.1889 C26H30O7 5
9 17.8 15.6 213, 289, 321 461.1952 461.1940 C26H30O6 16
10 19.1 17.2 209, 296, 341 463.1741 463.1733 C25H28O7 8
11 19.9 18.3 nd 475.2089 475.2097 C27H32O6 2
12 19.9 18.3 273, 304, 363 461.1585 461.1576 C25H26O7 1
13 20.3 19.3 208, 292, 336 447.1788 447.1784 C25H28O6 10
14 22.8 22.0 213, 294, 318, 340 461.1949 461.1940 C26H30O6 16
15 23.7 23.2 246, 394 461.1937 461.1940 C26H30O6 16
16 24.6 24.4 242, 295, 321 431.1839 431.1834 C25H28O5 10
aRetention time in the HPLC–PDA–ESITOFMS analysis, b retention time in the semi-preparative HPLC separation, c hits in the natural products
database (Chapman and Hall Dictionary of Natural Products); search query limited by the term “Sophora” and the corresponding molecular formula
nd Not determined



















1 R 1= -OH, R2 = OCH3, R3,R4, = OH
2 R1 = -OH, R2 = OCH3, R3,R4, = OH
3 R1 = H, R2 = OCH3, R3,R4, = OH
4 R1 = -OH, R2,R3,R4, = OH
5 R1 = H, R2,R4 = OH, R3 = OCH3
6 R1 = H, R2,R3,R4, = OH
7 R1 = -OH, R2 = OCH3, R3,R4, = OH
8 R1 = -OH, R2 = OCH3, R3,R4, = OH
9 R1 =H, R2 = OCH3, R3,R4, = OH
10 R1 = -OH, R2,R3,R4, = OH
11 R1 = H, R2,R3 = OCH3, R4, = OH
13 R1 = H, R2,R3,R4, = OH
14 R1 = H, R2,R4 = OH, R3, = OCH3
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Fig. 5 a HSQC spectrum of kushenol Y (4) recorded with the TXI probe after HPLC peak collection and b HMBC spectrum and key correlations
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Fig. 6 a Potentiation of IGABA through α1β2γ2S GABAA receptors
by 10 µM of norkurarinol (0 ± 0%, n = 2), kushenol I (216.5 ±
29.3%, n = 5), (−)-kurarinone (362.3 ± 23.8%, n = 5), kushenol X
(21.6 ± 3.4%, n = 2), neokurarinol (13.7 ± 4.6%, n = 2), kushenol C
(0±0%, n = 2), sophoraflavanone G (211.6±18.6%, n = 3), leachia-
none A (13.1±5.1%, n = 2), kuraridine (719.7±140.3%, n = 3), and
kushenol A (53.1 ± 3.1%, n = 2). b Representative currents through
α1β2γ2S GABAA receptors induced by GABA (EC3−10, single bar,
control) and traces recorded during co-application of GABA (EC3−10)
and the indicated compound (double bar). Current potentiation induced
by the four most active compounds, kushenol I (7), (−)-kurarinone (9),
sophoraflavanone G (13), and kuraridine (15) is shown
The major peak was attributed to (−)-kurarinone (9), the
main lavandulyl flavonoid in S. flavescens. The remain-
ing compounds were all structurally related 8-lavandulyl
flavonoids (Fig. 4) which were identified as kushenol H (1),
kushenol K (2), kurarinol (3), kushenol P (5), norkurari-
nol (6), kushenol I (7), kushenol N (8), (−)-kurarinone (9),
kushenol X (10), neokurarinol (11), kushenol C (12), sopho-
raflavanone G (13), leachianone A (14), kuraridine (15), and
kushenol A (16) by comparison of their MS, UV, and NMR
spectra with published reference data [21–27].
A new but pharmacologically inactive flavonoid 4 was
obtained as a light yellow amorphous powder. Its molecular
formula C25H30O8 was deduced from HR-ESIMS (M+Na+
found 481.1846, calcd. 481.1838).The UV spectrum showed
absorption maxima at 287 and 326 nm. The 1H-NMR spec-
trum revealed the presence of a 1,2,4-trisubstituted aromatic
ring at δH 7.28 (d, 1H, J = 8.0 Hz, H-6′), 6.39 (dd, 1H,
J = 8.0, 2.1 Hz, H-5′) and 6.35 (d, 1H, J = 2.1 Hz, H-
3′), an isolated aromatic proton at δH 5.96 (s, 1H, H-6), and
two protons at δH 4.74 (d, 1H, J = 11.6 Hz, H-3) and 5.39
(d, 1H, J = 11.6 Hz, H-2) characteristic of 2,3-trans-fla-
vanonol derivatives [24]. Additional signals at δH 1.11 (s,
6H, H-6′′, 7′′), 1.23 (m, 2H, H-3′′), 1.35 (m, 2H, H-4′′),
1.59 (s, 3H, H-10′′), 2.38 (m, 1H, H-2′′), 2.42 (m, 2H, H-
1′′), 4.52 (s, 1H, H-9′′), and 4.59 (s, 1H, H-9′′) were attrib-
utable to a 5-hydroxy-2-isopropenyl-5-methylhexyl moiety
and were virtually superimposable with data reported for lav-
andulyl moieties of related flavonoids such as kushenol H (1)
[21]. Compared to 1 the only difference in the spectrum of 4
observed was a hydroxy group at C-5 instead of a methoxy
residue in 1. The 13C-NMR spectrum of 4 contained sig-
nals of four oxygenated aromatic carbons and one carbonyl
carbon. Chemical shifts and signal patterns in the 1H- and
13C-NMR spectra indicated that the hydroxyl groups were
at C-5, C-7, C-2′, and C-4′.These assignments and the posi-
tion of the side chain were further confirmed by HSQC and
HMBC experiments. Representative spectra obtained with
the 1 mm TXI probe after HPLC peak collection are shown
in Fig. 5. As in other lavandulyl flavonoids reported from S.
flavescens, the absolute configuration at C-2′′ has not been
determined [24]. The CD spectrum of 4 showed a posi-
tive absorption at [θ ]315 + 5897 and a negative absorption
at [θ ]293 − 17061, from which the absolute configuration
at C-2 and C-3 were determined as 2R and 3R, respec-
tively [28]. Thus, 4 was (2R,3R)-8-(5-hydroxy-2-isopro-
penyl-5-methylhexyl)-5,7,2′,4′-tetrahydroxyflavanonol. We
named the compound kushenol Y, in accord with trivial
names of related lavandulyl flavonoids from S. flavescens.
For further evaluation of compounds in the active time
windows, 6, 7, and 9–16 (10 µM) were co-applied with
a GABA (EC3−10) to oocytes expressing α1β2γ2S recep-
tors. Kushenol I (7), (−)-kurarinone (9), sophoraflavanone
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Fig. 7 Concentration–response curves for IGABA enhancement by a
kushenol I (EC50 = 5.0 ± 2.3 µM, nH = 1.3 ± 0.3, n = 5); b (−)-ku-
rarinone (EC50 = 8.1±1.4 µM, nH = 1.9±0.1, n = 4); c sophoraflav-
anone G (EC50 = 15.0±3.6 µM, nH = 1.5±0.2, n = 3); and d kurari-
dine (EC50 = 4.0±2.4 µM, nH = 0.9±0.1, n = 3) in Xenopus oocytes
expressing GABAA receptors composed of α1, β2, and γ2S subunits. A
maximum potentiation of IGABA by kushenol I (a, 267.6 ± 56.6%, n =
5), (−)-kurarinone (b, 578.5 ± 68.8%, n = 4), sophoraflavanone G (c,
604.9 ± 108.2%, n = 3), kuraridine (d, 891.5 ± 163.0%, n = 3) was
observed. e Representative currents through α1β2γ2S GABAA recep-
tors in the presence of GABA (EC3−10, single bar, control) and cur-
rents recorded during co-application of GABA (EC3−10) and 0.001,
0.01, 0.1, 1, 10, and 100 µM of kuraridine (double bar)
G (13), and kuraridine (15) induced the strongest IGABA
enhancement (Fig. 6). For these compounds the concen-
tration–response relationships for IGABA enhancement were
determined (Fig. 7). Given the lack of activity in other frac-
tions of the activity profile (Fig. 1), the other flavonoids were
considered as inactive. Interestingly, application of saturating
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concentrations of kushenol I (7), (−)-kurarinone (9), soph-
oraflavanone G (13), and kuraridine (15) induced chloride
inward currents in the absence of GABA. These currents did
not exceed 10% of the maximal IGABA induced by a sat-
urating GABA concentration (1 mM). This partial agonist
activity was most pronounced for kuraridine (15) (Fig. 8).
(−)-Kurarinone (9) and kuraridine (15) are the first
representatives of a new scaffold of GABAA receptor mod-
ulators with a flavonoid moiety. Interaction with GABAA
receptors have been investigated since the 1980s, when
first evidence was produced from displacement studies
with radiolabelled benzodiazepines [29]. Subsequent binding
studies demonstrated that a range of naturally occurring
and synthetic flavonoids including the monomeric flavo-
noids apigenin [30], 6-hydroxyflavone [31], baicalin [32],
hesperidin, and 6-methylapigenin [33,34], and biflavonoids
such as agathisflavone and amentoflavone [35–37] bind
to GABAA receptors with nanomolar affinity. Querce-
tin, apigenin, morine, and chrysin have been shown to
inhibit IGABA through α1β1γ2sGABAA receptors [38]. Sim-
ple flavones appear to interact with the benzodiazepine
binding site [34,39], whereas amentoflavone is a negative
modulator of GABAA receptors whose action appears inde-
pendent of benzodiazepine modulatory sites on the recep-
tor [36]. Evidence for in vivo activity mediated through
GABAA receptor modulation has been reported for selected
flavonoids. Simple flavones and flavonols such as chry-
sin, apigenin, wogonin, 6-methylapigenin, hispidulin, and
luteolin-7-O-(2-rhamnosylglucoside) appear to induce pre-
dominantly anxiolytic effects and seem less efficient as sed-
atives, anticonvulsants, and myorelaxants [34,39–42].
The pharmacology of Sophora flavescens flavonoids has
been intensively studied. Neuroprotective [43] and anti-
inflammatory [44] properties have been reported, but no phar-
macological effects that could be related to modulation of
GABAA receptors. Given the close structural relationship of
1–16, some preliminary structure activity considerations can
be derived from this focused library via our activity profil-
ing approach (Fig. 9): The compounds differ in some spe-
cific attributes, namely in the substitution at C-5′′ of the side
chain, the substituents at C-5, C-2′, and C-4′ of the flavo-
noid moiety, and in the nature of the basic flavonoid struc-
ture, viz. flavanone, flavanonol or chalcone. Absence of a
hydroxy group at C-5′′ of the side chain appears essential, as
compounds 1-6 bearing a hydroxyl group were all inactive.
The methoxy substituent at C-5 contributes to activity, since
all compounds with a hydroxy group either showed less (eg.
13) or no activity. Comparison of (−)-kurarinone (9) and ku-
shenol A (16) indicates that a hydroxy group at C-4′ also
contributes to activity. Active compounds bear a hydroxy
substituent at C-2′ instead of a methoxy group as, for exam-
ple, in neokurarinol (11). Flavanone (e.g., 9) and chalcone
derivatives (e.g., 15) show higher activity than corresponding
Fig. 8 Activation of GABAA receptors by kushenol I, (−)-kurarinone,
sophoraflavanone G, and kuraridine. a Bar graphs illustrate the ampli-
tudes of chloride currents induced in the absence of GABA by saturat-
ing concentrations of kushenol I (1.0 ± 0.2%, n = 3), (−)-kurarinone
(3.7 ± 1.1%, n = 3), sophoraflavanone G (2.1 ± 0.4%, n = 3),
and kuraridine (5.0 ± 2.2%, n = 3). 100% correspond to the maxi-
mal IGABA induced by a saturating concentration (1 mM) of GABA. b
Representative currents illustrating direct activation of GABAA recep-
tors (α1β2γ2S) by kushenol I, (−)-kurarinone, sophoraflavanone G, and
kuraridine in comparison to IGABA induced by 1 µM GABA
flavanonol derivatives (7 and 8). In summary, it appears
that several structural features contribute to some degree to
the GABAA receptor modulating properties of 8-lavandulyl
flavonoids and that absence of a hydroxyl group at C-5′′ is
essential (Fig. 5).
The discovery of a new scaffold for potent GABAA
modulators (EC50s between 5.0 and 15.0 µM) enlarges the
spectrum of natural products acting on this target. The
example of 8-lavandulyl flavonoids highlights the advan-
tages of an HPLC-based approach, in particular, the pos-
sibility of obtaining valuable preliminary structure–activity
information via the rapid characterization of structurally
related compound series. (−)-Kurarinone (9) fulfils most cri-
teria of Lipinski’s rule of five [45] and has a polar surface
area that may enable CNS penetration [46]. We currently
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Fig. 9 Summary of preliminary structure activity information on lav-
andulyl flavonoids and calculated physicochemical data for (−)-kurari-
none (9) (from Pubchem)
investigate the binding site of the most active compounds 9
and 15, their subunit specificity, and in vivo activity.
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